Lifetime Achievement in Cancer Research Prize
IMPORTANT UPDATE - 2 April 2020
This prize honours an individual who has demonstrated a lifetime commitment to the fight against cancer, making exceptional advances in the field, and has made significant contributions through research, leadership, collaboration and/or mentorship.
Established independent researchers
Postponed until Spring 2021
Postponed until Spring 2021
In addition to the honorarium and commemorative trophy, the Lifetime Achievement Prize winner is invited to deliver a plenary lecture at the CRUK Researchers' Retreat.
Make a nomination
Ready to nominate an outstanding researcher?
Make a nomination
The Lifetime Achievement in Cancer Research Prize is awarded annually to an outstanding cancer researcher nominated by his or her peers and selected by an international panel.
- Nominations may be made on behalf of individuals who are living at the time of the nomination.
- Candidates cannot nominate themselves.
- Candidates need not be in receipt of funding from Cancer Research UK, or have been supported, either directly or indirectly, by Cancer Research UK funding.
- The candidate’s research can be aligned with any fields covered by our Research Strategy, including work to improve the prevention, diagnosis, and optimisation of cancer treatments.
- The current geographical location of the candidate does not affect their eligibility; however, a significant proportion of their research output must arise from work performed in the UK.
- There are no restrictions regarding the race, gender, nationality, or religious or political views of the candidate.
- The Prize will be presented to an individual investigator.
- Institutions or organisations are not eligible for the Prize.
Cancer Research UK is committed to promoting equality, diversity and inclusion. We’re seeking nominations from a diverse range of backgrounds for this Prize.
The application process has two stages:
- the nominator proposes the candidate
- the candidate is then invited to confirm nomination and provide supporting documents
To make a nomination, please submit the name and host institute of the candidate to firstname.lastname@example.org. Candidates will be contacted and invited to confirm their nomination to be considered by our CRUK Prizes Panel.
Nominators are invited to submit a letter of support detailing the candidate’s scientific discoveries or body of work; how these contributions have had a lasting impact on the field; and how he/she has demonstrated a lifetime commitment to the fight against cancer.
Paper nominations will not be accepted. A nomination should not be considered submitted until Cancer Research UK has issued an email confirming this. Confirmations will be sent within five working days of the submission deadline.
Nominated Candidates will be contacted by CRUK and invited to confirm their nomination to be considered at the next CRUK Research Prizes Panel Meeting.
The following materials must be submitted with the confirmation:
- Candidate’s CV, summarising positions held (including Orchid ID)
- Two Letters of Support from independent experts in the field (one can be the nominator) detailing how the candidate’s scientific discoveries or body of work; how these contributions have had a lasting impact on the cancer field; and how he/she has demonstrated a lifetime commitment to the fight against cancer through research, leadership, collaboration and/or mentorship.
- A 1–2 page application statement, detailing key research achievements and their impact/influence on the field.
Confirmation of nominations must be submitted electronically to email@example.com.
Nominations, and confirmation of nominations including submission of supporting documents, must be sent electronically to firstname.lastname@example.org by 9 April 2020 (3pm BST).
Winners of the Lifetime Achievement Prize
Professor Stephen West
Title: 2018 winner
The Francis Crick Institute
Professor Stephen West is an internationally renowned expert on DNA recombination and repair who has made ground-breaking discoveries that reveal the molecular mechanisms of these processes, with profound impact on cancer prevention and therapy. His discoveries accelerated our understanding of the role of BRCA2 in inheritable breast, prostate and ovarian cancers, and showed how BRCA mutations are linked to defective recombination processes, with huge implications for cancer prevention and therapy.
Professor Jack Cuzick
Title: 2017 winner
Director of the Wolfson Institute of Preventive Medicine, Head of the Centre for Cancer Prevention, and John Snow Professor of Epidemiology
Queen Mary University of London
Professor Jack Cuzick FRS, FMedSci, FRCP(hon) is a population researcher whose work on screening, risk prediction and prevention has had an immense impact. He is internationally recognised for his role in developing the field of chemoprevention of breast cancer. More recently, he has been a leader in the introduction of aromatase inhibitors, both for the treatment and chemoprevention of breast cancer.
Jack also made valuable contributions to assessing the risk of developing breast cancer. His risk model is now used all over the world, especially in family history and genetics clinics. After identifying late-mortality from breast irradiation, his work has guided changes to the way in which radiotherapy is delivered. He has also made key contributions to cancer screening, notably in cervical and colorectal cancer. He pioneered HPV testing for primary screening, and has been a major contributor to the evaluation of other cancer screening modalities. He has also been a great ambassador and advocate for the adoption of screening where it has been shown to be beneficial.
Jack has been an outstanding leader in the cancer research field over many years, and has been central in building the capacity of our world-leading population research. As the John Snow Professor of Epidemiology he has developed the Centre for Cancer Prevention, from its origins in the ICRF Lincoln's Inn Fields to the Wolfson Institute at Queen Mary University of London. Having originally trained in mathematics and physics in his native California, Jack's career is a shining example of the power of bringing diverse disciplines together in our community.
Professor Stan Kaye
Title: 2016 winner
Consultant Clinical Oncologist and Emiritus Professor of Medical Oncology
The Royal Marsden hospital and The Institute of Cancer Research, London
Professor Stan Kaye FRSE FMedSci is a clinical oncologist and scientist who has had a profound impact on patients and on the clinical trials landscape in the UK. Stan was instrumental in setting up early-phase clinical trials groups at the University of Glasgow and at The Institute of Cancer Research and The Royal Marsden in London. Under his leadership, these groups have grown into powerhouses of drug development, and are an essential component of our research infrastructure. In addition to his role in developing new drugs that are now benefiting patients in routine clinical use, such as abiraterone and olaparib, his research has contributed to our understanding of how drug resistance arises and can be tackled. He has also been an exceptional mentor and role model for a new generation of medical oncologists and clinical researchers.
Stan qualified in medicine at the University of London in 1972, and was appointed to the Chair of Medical Oncology at the University of Glasgow in 1985. He moved to The Institute of Cancer Research and The Royal Marsden in 2000, officially retiring in 2014 but remaining active in the research community.
Professor Mel Greaves
Title: 2015 winner
Professor of Cell Biology
The Institute of Cancer Research, London
Professor Mel Greaves FMedSci FRS is a world-leading expert in childhood leukaemia and cancer evolution. His research into the immunology and molecular biology of leukaemia have transformed our understanding of the disease, and paved the way for more effective and personalised treatment of the disease. He has also pioneered the application of evolutionary biology in cancer research, producing important insights into the aetiology and pre-clinical development of leukaemia.
At the Institute of Cancer Research, Professor Greaves led the Leukaemia Research Fund Centre for Cell and Molecular Biology, and more recently founded the Centre for Cancer Evolution. In addition to his outstanding research achievements, he has had a significant impact as a teacher and mentor, and has been inspiration in his extensive public engagement activities, which include publishing two popular science books about cancer research.
Professor Ron Laskey
Title: 2014 winner
Emeritus Professor of Animal Embryology
The Gurdon Institute, University of Cambridge
Professor Ron Laskey CBE FMedSci FRS is a leading cell and molecular biologist who has made many important discoveries with substantial impact on our understanding of cancer and its control. His research into the machinery of DNA synthesis has transformed our understanding of the cell cycle, with significant implications for the early diagnosis of cancer. This work led to the discovery of several proteins that are overexpressed in cancer cells, several of which are now being used to develop novel cancer screening tools. He has also been extremely productive in the field of molecular transport, illuminating the processes of nuclear macromolecular transport.
Professor Laskey was Charles Darwin Professor of Animal Embryology at the University of Cambridge from 1983 until 2011. During this time he co-founded the Wellcome Trust/CRUK Gurdon Institute and was founder Director of the MRC Cancer Cell Unit. He has served as president of both the Biochemical Society and the British Society for Cell Biology, and as vice-president of the Academy of Medical Sciences. Alongside his extraordinary scientific achievements, as a teacher and mentor he has made a great impact inspiring a generation of successful researchers.
Professor Sir Bruce Ponder
Title: 2013 winner
Emeritus Professor & Head of Department of Oncology
University of Cambridge
Director of the Cancer Research UK Cambridge Institute
Professor Sir Bruce Ponder FMedSci FRS is a leading geneticist whose research and leadership in the field of cancer genetics has had profound impact on the prevention, detection and treatment of cancer. In the 1970s, he pioneered the investigation of cancer predisposition genes in the UK using cutting-edge methods of linkage analysis to map genes. He identified ret as the predisposing gene for Multiple Endocrine Neoplasia Type 2 Syndrome. His leadership has helped the field of cancer genetics flourish, with many more high-profile discoveries being made and real impact achieved through clinical genetics and drug discovery.
Professor Ponder was Director of the Cancer Research UK Cambridge Institute and the Cambridge Cancer Centre. In addition to his scientific achievements, he is recognised for his work building an integrated infrastructure for cancer research. He played a central role in creating the OECI accredited comprehensive cancer centre at Cambridge, bringing together science at the University of Cambridge with the oncology clinic at Addenbrooke’s Hospital.
Professor Sir David Lane
Title: 2012 winner
Professor of Oncology
University of Dundee
Professor Sir David Lane FRCP FRCSEd FMedSci FRS FRSE is a leading molecular biologist and immunologist. He is recognised worldwide for his contribution to the discovery of the first natural tumour suppressor protein and gene, p53, which he famously dubbed the "guardian of the genome". Subsequent research has established p53 as one of the most important discoveries in cancer research, showing it to have several critical functions and to be mutated in more than half of all cancers. Professor Lane has devoted much of his career to understanding the function of p53, and how it might be targeted therapeutically.
Alongside this research, Professor Lane has been an inspirational leader in the cancer research community. He helped to inform the successful merger of the organisations which formed Cancer Research UK, and served as Chief Scientist until 2010. Since receiving the 2012 Lifetime Achievement Prize, he has taken up the position of Chief Scientist at the Agency for Science, Technology and Research (A*STAR) in Singapore.
Professor Chris Marshall
Title: 2011 winner
Professor of Cell Biology and Director of Research
The Institute of Cancer Research
Professor Chris Marshall FMedSci FRS was a leading cell biologist who made pioneering discoveries in the field of cell signalling with substantial impact on our understanding of cancer and its control. Most notable amongst his discoveries are the identification of the oncogene NRAS, and his contribution to deciphering the MAPK/ERK signalling cascade. His work laid the foundations for many of subsequent discoveries in oncogene and cell signalling research, and has had a profound impact for the development of targeted therapies which exploit oncogene addictions.
Professor Marshall was Professor of Cell Biology and Director of Research at the Institute of Cancer Research, London, until his death in 2015. He served for several years as Chair of the Cancer Research UK Science Committee.
Professor Sir Richard Peto
Title: 2010 winner
Professor of Medical Statistics and Epidemiology, and co-director of the Clinical Trial Service Unit and Epidemiological Studies Unit
University of Oxford
Professor Sir Richard Peto FRS is a leading medical statistician and epidemiologist. His contributions to our understanding of the aetiology of cancer have had profound impact on prevention of the disease. In the 1970s he worked with Sir Richard Doll on the pioneering studies of smoking and mortality in British doctors which established the long-term health risks of smoking. His research has formed the foundation for shifts in tobacco policy worldwide, not least because of his own policy advocacy efforts.
Professor Peto has also had substantial influence on Clinical Trial methodology, including developing the log-rank test and techniques which underpin meta-analysis. By laying this groundwork, he has had an enormous impact on clinical practice not only in oncology but in a great many fields worldwide.